Logo 1 Logo 2

Clinical Trial Details

Trial ID: L2497
Source ID: NCT00343980
Associated Drug: Rosiglitazone
Title: Safety and Efficacy of Inhaled Pre-prandial Human Insulin in Type 2 Diabetes
Acronym:
Status: TERMINATED
Study Results: NO
Results:
Conditions: Diabetes|Diabetes Mellitus, Type 2
Interventions: DRUG: rosiglitazone|DRUG: inhaled human insulin|DRUG: glimepiride
Outcome Measures: Primary: Treatment difference in HbA1c, After 26 weeks | Secondary: Adverse events, For the duration of the trial|Body weight, during treatment|Lung function, after 26 weeks of treatment|Blood glucose, after 26 weeks of treatment|Hypoglycaemia, from 12-26 weeks of treatment
Sponsor/Collaborators: Sponsor: Novo Nordisk A/S
Gender: ALL
Age: ADULT, OLDER_ADULT
Phases: PHASE3
Enrollment: 363
Study Type: INTERVENTIONAL
Study Designs: Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT
Start Date: 2006-10-10
Completion Date: 2008-03-10
Results First Posted:
Last Update Posted: 2017-03-01
Locations: Novo Nordisk Investigational Site, St Leonards, New South Wales, 2065, Australia|Novo Nordisk Investigational Site, Wollongong, New South Wales, 2500, Australia|Novo Nordisk Investigational Site, Garran, 2605, Australia|Novo Nordisk Investigational Site, Kingswood, 2747, Australia|Novo Nordisk Investigational Site, Osijek, 31 000, Croatia|Novo Nordisk Investigational Site, Zagreb, 10 000, Croatia|Novo Nordisk Investigational Site, Chennai, Tamil Nadu, 600086, India|Novo Nordisk Investigational Site, Vellore, Tamil Nadu, 632004, India|Novo Nordisk Investigational Site, Bangalore, 560010, India|Novo Nordisk Investigational Site, Chennai, 600020, India|Novo Nordisk Investigational Site, Coimbatore, 641002, India|Novo Nordisk Investigational Site, Skopje, 1000, Macedonia, The Former Yugoslav Republic of|Novo Nordisk Investigational Site, Cebu City, 6000, Philippines|Novo Nordisk Investigational Site, Makati City, 1200, Philippines|Novo Nordisk Investigational Site, Manila, 1000, Philippines|Novo Nordisk Investigational Site, Moscow, 119034, Russian Federation|Novo Nordisk Investigational Site, Moscow, 121356, Russian Federation|Novo Nordisk Investigational Site, Moscow, 127486, Russian Federation|Novo Nordisk Investigational Site, Moscow, 127644, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, 194354, Russian Federation|Novo Nordisk Investigational Site, Saint-Petersburg, 198013, Russian Federation|Novo Nordisk Investigational Site, Bornova-IZMIR, 35100, Turkey|Novo Nordisk Investigational Site, Bursa, 16059, Turkey|Novo Nordisk Investigational Site, Istanbul, 34098, Turkey|Novo Nordisk Investigational Site, Istanbul, 34390, Turkey|Novo Nordisk Investigational Site, Istanbul, 34718, Turkey
URL: https://clinicaltrials.gov/show/NCT00343980

Drug ID Drug Name Type DrugBank ID Targets Category Latest Progress
D116 Rosiglitazone small molecule DB00412 Details